Aarti Drugs : Q4FY17 Result
Nidhi Jani / 23 May 2017
The company reported PAT of Rs 20.7 crore which represents a sequential QoQ increase of 16.1 per cent and a YoY increase of 11.5 per cent.
Aarti Drugs reported its results for the quarter ended March 31, 2017 on Tuesday.
The company's total sales for Q4FY17 came in at Rs 298.9 crore, which represents a 3.2 per cent sequential increase and 4.8 per cent YoY decline.
Its operating profit (EBIT) for the quarter amounted to Rs 35.9 crore and its EBIT margin stood at 12 per cent.
The company reported PAT of Rs 20.7 crore which represents a sequential QoQ increase of 16.1 per cent and a YoY increase of 11.5 per cent.
The stock opened at Rs 521.55 and touched intra-day high and low of Rs 537 and Rs 515, respectively on the BSE.
Aarti Drugs is a phamaceutical company having manufacturing facilities at Tarapur and Sarigam. The company manufactures vitamins, anti-arthritis, anti-fungal, antibiotics, ACE inhibitors, anti-diabetic, anti-cholinergic, sedatives and anti-depressant drugs. Its product portfolio consists of APIs, steroids, SPR steroids, speciality chemicals and pharma intermediates.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.